Sign in
CompletedPhase 4

NLR and PLR Levels Following PENG Block in Hip Arthroplasty

Key facts

Who runs it
Poznan University of Medical Sciences
Where
Poland1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
Phase
Phase 4
People taking part
60 people enrolled
Started
16 Jun 2025
Ended
9 Dec 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • 0.9% Sodium Chloride Injection
  • Ropivacaine 0.2% Injectable Solution
Record updated
29 December 2025

Who can take part

Age
60 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 11 criteriaShow less

Who can take part

  • Patients with ASA classification I-III
  • Aged 60-100 years
  • Who will be scheduled for hip arthroplasty under spinal anesthesia

Who cannot take part

  • Take anticoagulant therapy
  • Patients who have a history of bleeding diathesis
  • History of chronic pain before surgery
  • patients unable to assess their pain (dementia)
  • patients having an infection in the region of the procedure
  • Multiple trauma
  • patients operated under general anesthesia
  • the patient who does not accept the procedure

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Effect of PENG block on NLR and PLR following hip arthroplasty

The 2 groups in the trial

  • Sham blocksPlacebo, for comparison

    PENG block with 20ml of 0.9% sodium chloride

    Treatment: 0.9% Sodium Chloride Injection

  • PENG blockExisting treatment, for comparison

    PENG block with 20ml 0f 0.2% ropivacaine

    Treatment: Ropivacaine 0.2% Injectable Solution

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Pericapsular Nerve Group Block Mitigates Surgical Stress and Enhances Analgesia in Total Hip Arthroplasty: A Randomized Controlled Trial
Record updated
29 December 2025